Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib by Maheen Z. Abidi, Javeria Haque, Parvathi Varma, Horatiu Olteanu, Guru Subramanian Guru Murthy, Binod Dhakal, Parameswaran Hari

Get full text

Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy by Luciano J. Costa, Eva Medvedova, Binod Dhakal, Bhagirathbhai R. Dholaria, Kelly N. Godby, Susan Bal, Gayathri Ravi, Smith Giri, Saurabh Chhabra, Rebecca Silbermann, Natalie S. Callander

Get full text

Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma by Lawrence G Lum, Parameswaran Hari, Aniko Szabo, Michele Donato, Jee Hyun Park, Daniel H Fowler, Binod Dhakal, Saurabh Chhabra, Deborah D Glass, David S Siegel, Tania C Felizardo

Get full text

A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings by Steven P. Treon, Camille N. Kotton, David J. Park, Giorgia Moranzoni, Camilla K. Lemvigh, Joseph C. Gathe, Tilly A. Varughese, Christopher F. Barnett, Johnny M. Belenchia, Nina M. Clark, Charles M. Farber, Muhammad Bilal Abid, Gulrayz Ahmed, Christopher J. Patterson, Maria L. Guerrera, Jacob D. Soumerai, Vipheaviny A. Chea, Isabel P. Carulli, Jackson Southard, Shuqiang Li, Catherine J. Wu, Kenneth J. Livak, Eric Holmgren, Pil Kim, Carrie Shi, Holly Lin, Vanitha Ramakrishnan, Ying Ou, Scott Olszewski, Lars Rønn Olsen, Derin B. Keskin, Derin B. Keskin, Zachary R. Hunter, Christopher Tankersley, Todd Zimmerman, Binod Dhakal

Get full text